Local administration of immunotherapy for patients with skin cancer: A systematic review

J. C. Janssen; B. van Dijk; L. L. Hoeijmakers; D. J. Grünhagen; W. M. Bramer; C. Verhoef; T. D. de Gruijl; C. U. Blank; A. A.M. van der Veldt

doi:10.1016/j.ctrv.2024.102848

Local administration of immunotherapy for patients with skin cancer: A systematic review

J. C. Janssen, B. van Dijk, L. L. Hoeijmakers, D. J. Grünhagen, W. M. Bramer, C. Verhoef, T. D. de Gruijl, C. U. Blank, A. A.M. van der Veldt^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

8 Downloads (Pure)

Abstract

Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.

Original language	English
Article number	102848
Journal	Cancer Treatment Reviews
Volume	131
DOIs	https://doi.org/10.1016/j.ctrv.2024.102848
Publication status	Published - Dec 2024

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ctrv.2024.102848Licence: CC BY

PIIS0305737224001774Final published version, 1.63 MBLicence: CC BY

Cite this

@article{7ff071568ce4413392171a4c89f1504b,

title = "Local administration of immunotherapy for patients with skin cancer: A systematic review",

abstract = "Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.",

author = "Janssen, {J. C.} and {van Dijk}, B. and Hoeijmakers, {L. L.} and Gr{\"u}nhagen, {D. J.} and Bramer, {W. M.} and C. Verhoef and {de Gruijl}, {T. D.} and Blank, {C. U.} and {van der Veldt}, {A. A.M.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2024",

month = dec,

doi = "10.1016/j.ctrv.2024.102848",

language = "English",

volume = "131",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

}

TY - JOUR

T1 - Local administration of immunotherapy for patients with skin cancer

T2 - A systematic review

AU - Janssen, J. C.

AU - van Dijk, B.

AU - Hoeijmakers, L. L.

AU - Grünhagen, D. J.

AU - Bramer, W. M.

AU - Verhoef, C.

AU - de Gruijl, T. D.

AU - Blank, C. U.

AU - van der Veldt, A. A.M.

PY - 2024/12

Y1 - 2024/12

N2 - Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.

AB - Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.

UR - http://www.scopus.com/inward/record.url?scp=85207789378&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2024.102848

DO - 10.1016/j.ctrv.2024.102848

M3 - Review article

C2 - 39486396

AN - SCOPUS:85207789378

SN - 0305-7372

VL - 131

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

M1 - 102848

ER -

Local administration of immunotherapy for patients with skin cancer: A systematic review

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this